Vivos Therapeutics
VVOS
19 hedge funds and large institutions have $1.27M invested in Vivos Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
27% more capital invested
Capital invested by funds: $1M → $1.27M (+$271K)
0.87% more ownership
Funds ownership: 5.96% → 6.83% (+0.87%)
10% less funds holding
Funds holding: 21 → 19 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$356K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$51.8K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$17.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$111K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$45.4K |
| 3 |
EL
EWA LLC
Pittsbugh,
Pennsylvania
|
-$29.8K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$650 |
| 5 |
Morgan Stanley
New York
|
-$629 |
VVOS Hedge Fund Activity: Q2 2025 in Review
19 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q2 2025, worth a combined $1.27M — up 27% from $1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VVOS and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was UBS Group, adding an estimated $356K. The largest seller was Envestnet Asset Management, exiting entirely with an estimated $111K sold.
- 19 institutional investors held Vivos Therapeutics (VVOS) as of Q2 2025, down from 21 in Q1 2025.
- Funds reported $1.27M of Vivos Therapeutics stock for Q2 2025, up 27% quarter-over-quarter.
- 4 funds opened new Vivos Therapeutics positions in Q2 2025 and 5 closed out, a net change of -1 holder.
- The largest Vivos Therapeutics buyer in Q2 2025 was UBS Group, an estimated $356K added.
- The largest Vivos Therapeutics seller in Q2 2025 was Envestnet Asset Management, an estimated $111K sold.
Based on aggregated 13F filings for Q2 2025.